Impact of pre- and post-treatment ctDNA positivity on outcomes in NSCLC
Real-world ctDNA levels provide significant prognostic value before and after therapy
(A) Pre-1L
(B) 14-90 days post-1L
Kaplan-Meier survival curves comparing rwPFS for ctDNA >= 1% vs ctDNA < 1 % in pre- (A) and post- 1L treatment (B) biopsies from patients with NSCLC. Shaded areas represent the 95% confidence intervals. Median survival times (months) are specified. Log-Rank test P value is indicated.
Lens Library
